Liver and intrahepatic bile duct neoplasm

This phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…

This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This phase II trial tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) works better than chemotherapy alone for advanced biliary tract or gallbladder cancer. The study enrolls 57 adults who have not had prior treatment. Researc…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) before and after a standard tumor-burning procedure (radiofrequency ablation) can prevent small liver cancers from returning. About 202 adults with early-stage liver cancer will be randomly ass…

This early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests whether combining the drug regorafenib with a targeted radiation treatment (Y-90 radioembolization) can control liver cancer that cannot be removed by surgery. About 30 adults with this type of liver cancer will receive the combination therapy. The main goals are…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…

This study compares a new treatment called TheraSphere (tiny radioactive beads) to standard chemoembolization for people with liver cancer that cannot be removed by surgery. About 92 Chinese adults with early-to-mid stage liver cancer will be randomly assigned to one of the two t…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the …

This phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and contr…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…

This study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This phase 2 trial tests whether simvastatin, a widely used cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers change. The goal is to …

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancer live longer. About 810 participants received either durvalumab or a placebo alongside chemo. The study m…

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …

This trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to…

This study tested a combination of two chemotherapy drugs, irinotecan and carboplatin, as the first treatment for children and adults newly diagnosed with intermediate- or high-risk rhabdomyosarcoma, a type of muscle cancer. The goal was to see if this drug pair could shrink tumo…

This phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…

This study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…

This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…

This phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …

This phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…

This early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This study tests a combination of the drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) in 16 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink…

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not cand…

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…

This early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…

This early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handl…

This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including ovarian, endometrial, breast, and others) that have specific genetic changes or have stopped responding to similar treatments. The first phase finds…

This phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This study tests a new oil called T-ACE Oil, mixed with a chemotherapy drug, for people with liver cancer that cannot be removed by surgery. The oil is injected directly into the liver's blood vessels to block them and deliver chemo to the tumor. The trial aims to see if it is sa…

This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…

This phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This early-stage trial tests a new drug called BAY2965501, which boosts the immune system to fight cancer. It is given alone or with other drugs like pembrolizumab and chemotherapy. The study includes about 284 people with advanced solid tumors (skin, kidney, stomach, or lung can…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose and understand …

This program provides futibatinib (TAS-120) to adults with advanced bile duct cancer that has a specific FGFR2 gene change and who have no other treatment options. Participants take one 20 mg pill daily. The goal is to give access to this drug while it is being studied further.

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…

This global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …

This study is testing a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The microspheres are tiny glass beads containing radioactive yttrium-90, which are injected into the liver's blood vessels to deliver radiation directly to …

This early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This early-stage trial is testing a genetically modified herpes virus called RP3, alone or combined with the immunotherapy drug nivolumab, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best…

This early-phase study tests a genetically modified herpes virus (RP2) in 36 adults with advanced solid tumors that have not responded to standard treatments. The virus is designed to infect and destroy cancer cells while also stimulating the immune system. Some participants also…

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This early-phase study tests a portable device that sends gentle electric fields to the liver, combined with chemotherapy and a targeted drug (bevacizumab), in people whose cancer has spread to the liver and stopped responding to standard treatments. The main goal is to find the …

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This was a planned Phase 1 study to test NP-101, a drug made from black seed, in people with liver cancer that cannot be removed by surgery. Participants would have taken NP-101 daily for 28 days before receiving standard Y-90 radiation treatment. The goal was to find the safest …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…

This study aimed to test a new experimental drug called BC3402 combined with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The trial was withdrawn before any participants were enrolled, so no data on…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase 2 trial tests a combination of immunotherapy (camrelizumab), a targeted therapy (apatinib), and chemotherapy (gemcitabine and oxaliplatin) given before and after surgery for 30 people with advanced biliary tract cancer. The goal is to see if this approach can shrink tu…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…

This study tests a combination of two drugs, pembrolizumab and bavituximab, in 35 adults with advanced liver cancer that cannot be treated with surgery or local therapies. The goal is to see if the combination shrinks tumors and improves survival. Participants must not have had p…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This early-stage trial is testing a combination of two drugs—cadonilimab and regorafenib—in 30 adults with advanced liver cancer that has worsened after at least one prior therapy. The goal is to see if the combo can shrink tumors or slow the disease, while also checking for side…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This study tests an experimental drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose, and then expanding to see how well the drug shrinks tumors. About 725 parti…

This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…

This study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…

This study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacroli…

This early-stage study tests a new drug called GS-4528, given alone or with another cancer drug (anti-PD-1), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 participants will…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This pilot trial is testing whether adding stereotactic body radiation therapy (SBRT) to the standard transarterial chemoembolization (TACE) can better control liver cancer in patients waiting for a liver transplant. About 40 patients will be enrolled to see if the combination im…

This early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …

This Phase 2 study is testing a combination of three drugs—nanoliposomal irinotecan, fluorouracil, and leucovorin—in 48 adults with advanced biliary tract cancer that has progressed after initial chemotherapy. The main goal is to see if the treatment can stop the cancer from grow…

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …

This study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…

This early-phase trial tests a new immunotherapy called AGAR T cells in children with solid tumors such as liver cancer, Wilms tumor, and rhabdomyosarcoma that have returned or not responded to standard care. The cells are made from the patient's own T cells, which are geneticall…

This phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…

This Phase 3 trial is testing whether a new immunotherapy drug called AK112, when combined with standard chemotherapy, works better than another immunotherapy (durvalumab) plus the same chemo for people with advanced bile duct cancer. The study includes 682 participants who have …

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study is testing whether an AI tool (ChatGPT) can accurately identify abnormal cells in biopsy samples taken during an endoscopic ultrasound. About 136 adults with solid masses in the digestive tract will have their biopsy images reviewed by both the AI and expert pathologis…

This study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combinatio…

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…

This study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…

This study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion v…

This study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…

This early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or in…

This study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…

This early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…

This study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study compares a new bipolar knife to a standard monopolar knife for removing colon polyps using a procedure called endoscopic submucosal dissection (ESD). About 80 adults with colon growths will be randomly assigned to one knife. Researchers will measure how fast the proced…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…

This phase III trial compares two pain relief methods for patients undergoing open liver surgery for cancer: thoracic epidural analgesia and a four-quadrant TAP block. The study aims to see which method leads to a shorter hospital stay and better pain control. About 101 participa…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…

This study reviews medical records of 126 adults treated for liver or bile duct diseases (both non-cancerous and cancerous) since 2005. The goal is to see how well different treatments work and to find ways to improve survival, control symptoms, and lower risks. No new treatments…

This study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …

This study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study looks at whether an electronic cognitive test called BrainCheck can effectively screen mental function in 100 patients scheduled for liver surgery. Researchers will compare how well patients complete the digital test versus a traditional pen-and-paper assessment. The g…

This study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…

This study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study gathers blood, urine, stool, and tissue samples from 132 adults with primary liver cancer who are receiving or have received immunotherapy. Researchers will analyze these samples along with medical records to learn more about how liver cancer develops and responds to t…

This study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…

This study is a registry that will review medical records of 1,000 patients treated for benign or malignant gastrointestinal diseases between 2005 and 2030. Researchers will look at survival, symptoms like heartburn and swallowing trouble, and quality of life. The goal is to lear…

This study follows 10,000 adults with hepatocellular carcinoma (a type of liver cancer) to see how the disease changes over time and how different treatments affect patients in real life. Researchers are collecting information from regular doctor visits and patient surveys, and b…

This study is screening 1,000 patients at the HOPE clinic in Houston for liver fibrosis and cirrhosis using surveys, blood tests, and a non-invasive liver scan called FibroScan. The goal is to find early signs of liver damage that could lead to cancer, so that prevention or early…

This study planned to test a growth factor medicine (Increlex) in children aged 4-18 with chronic liver disease and short stature. The goal was to see if it could improve growth and quality of life. However, the study was withdrawn before any participants were enrolled, so no res…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This phase 2 trial tests whether a software-aided imaging system (Morfeus) can help doctors confirm that liver tumors are fully covered during ablation. About 107 patients with up to 3 liver tumors will be treated with standard ablation, and the software will be used to assess th…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study compares two catheters used during the mapping step before radioembolization for liver cancer. One is a standard microcatheter, the other is a pressure-enabled device (TriNav). The goal is to see if the pressure-enabled catheter delivers more radioactive tracer directl…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …

This study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare resu…

This study is testing a new blood test to see if it can find tiny bits of bile duct cancer left behind after treatment. Researchers will follow 100 adults who are having surgery to remove their cancer. The goal is to see if the test can predict if the cancer will come back sooner…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…

This study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This observational study will follow up to 500,000 adults with chronic liver disease or cirrhosis to understand how the disease progresses and how treatments are used in everyday practice. Researchers will collect data from medical records and patient reports to improve care and …

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study tests whether an automatic reminder in the electronic health record can increase the number of cirrhosis patients who get screened for liver cancer (hepatocellular carcinoma). The reminder prompts doctors to order a liver ultrasound when they see a patient with cirrhos…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…

This study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary l…

This study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at how social factors like income, education, and community support impact recovery in 500 children after liver transplant. Researchers will survey caregivers and interview families to understand barriers to good outcomes. The goal is to find ways to better integ…

This study is a registry that collects information from patients who have a procedure called percutaneous cholangiopancreatoscopy (PCPS). During PCPS, doctors use a tiny camera to see inside the bile ducts and remove stones or take tissue samples. The goal is to learn how well th…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …